Clinical trial
Vaccine Therapy in Treating Patients With Metastatic Solid Tumors
NCT00030693 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00030693 |
|---|---|
| Title | Vaccine Therapy in Treating Patients With Metastatic Solid Tumors |
| Official title | Intra-Lesional rF-B7.1 Versus rF-Tricom Vaccine In The Treatment Of Metastatic Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Biological, Other, Procedure |
| Interventions | recombinant fowlpox-B7.1 vaccine, recombinant fowlpox-TRICOM vaccine, laboratory biomarker analysis, quality-of-life assessment |
| Enrollment | 42 |
| Start date | Dec 1, 2001 |
| Primary completion | Apr 1, 2010 |
| First posted | Jan 27, 2003 |
| Last update posted | Jan 24, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: